Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew David Hellmann, Naiyer A. Rizvi, Jonathan Wade Goldman et al. · The Lancet Oncology · 2016
Cited by 963 works. doi:10.1016/s1470-2045(16)30624-6
Authors
- Matthew David Hellmann
- Naiyer A. Rizvi
- Jonathan Wade Goldman
- Scott N. Gettinger
- Hossein Borghaei
- Julie Renee Brahmer
- Neal Ready
- David E. Gerber
- Laura Q.M. Chow
- Rosalyn Anne Juergens
- Frances A. Shepherd
- Scott Andrew Laurie
- William J. Geese
- Tina C. Young
- Xuemei Li
- Scott Joseph Antonia
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer